Table 1. Pharmacological treatments tested for potential anti-allodynic effects in spinal cord-transected rats.
| Drugs | Pharmacological effect | Dose | Efficacy on biting behavior |
| Morphine | Opioid receptor agonist | 1, 3, 10 mg/kg s.c. | +++ |
| Tapentadol | Opioid receptor agonist and noradrenaline reuptake inhibitor | 10, 20 mg/kg i.p. | +++ |
| Ketamine | NMDA receptor antagonist | 50 mg/kg i.p. | ++ |
| Baclofen | GABA B receptor agonist | 10 mg/kg i.p. | + |
| Clonazepam | Benzodiazepine (agonist) | 0.25, 2 mg/kg i.p. | - |
| Gabapentin | Blockade of calcium channel α2δ subunit | 30, 100, 300 mg/kg i.p. | - |
| Pregabalin | Blockade of calcium channel α2δ subunit | 30 mg/kg i.p. | - |
| Amitriptyline | Tricyclic antidepressant | 10 mg/kg i.p. | - |
| Amitriptyline + Gabapentin | Tricyclic antidepressant + Blockade of calcium channel α2δ subunit | 10 mg/kg i.p. +100 mg/kg i.p. | - |
| Cyclotraxin B | TrkB receptor blocker | 20 mg/kg i.p. | - |
| Naratriptan | 5-HT1B/D receptor agonist | 0.1 mg/kg i.p. | - |
| Ondansetron | 5-HT3 receptor antagonist | 20 µg i.t. | - |
| 8-OH-DPAT | 5-HT1A/7 receptor agonist | 0.25 mg/kg i.p. | - |
+++: potent anti-allodynic effect (complete recovery of control mechanical sensitivity);
++: potent but short lasting anti-allodynic effect;
+: modest but significant anti-allodynic effect; -: inactive treatment.